Alembic Pharmaceuticals Limited (BOM: 533573)
India
· Delayed Price · Currency is INR
1,055.00
0.00 (0.00%)
At close: Dec 20, 2024
Alembic Pharmaceuticals Revenue
Alembic Pharmaceuticals had revenue of 16.48B INR in the quarter ending September 30, 2024, with 3.33% growth. This brings the company's revenue in the last twelve months to 63.57B, up 6.02% year-over-year. In the fiscal year ending March 31, 2024, Alembic Pharmaceuticals had annual revenue of 62.29B with 10.19% growth.
Revenue (ttm)
63.57B
Revenue Growth
+6.02%
P/S Ratio
n/a
Revenue / Employee
4.28M
Employees
14,858
Market Cap
207.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
Mar 31, 2020 | 46.06B | 6.71B | 17.06% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAlembic Pharmaceuticals News
- 10 days ago - Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil - Business Upturn
- 17 days ago - Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution - Business Upturn
- 26 days ago - Alembic Pharma shares surged nearly 5% today - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules - Business Upturn
- 6 weeks ago - Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY - Business Upturn